Certara, Inc.

Certara, Inc.(CERT)资讯与事件

$8.130

-0.147 (-1.81%)收盘时

CERT 资讯

CERT 事件

8/4 08:30

Certara Q2 Revenue $93.3M, Below Expectations

Reports Q2 revenue $93.3M, consensus $98.08M. "This second quarter was about continuing to execute on our commitments. Overall, we are pleased with our ongoing progress transforming Certara into a company we believe can deliver sustainable double-digit growth," said Jon Resnick, Chief Executive Officer. "We completed the divestiture of our Regulatory and Medical Writing business, implemented our two new business units, and taken necessary actions to strengthen our leadership team and our commercial model. Our focus in the second half of the year is customer impact and speed of execution."

8/4 08:30

Certara Reaffirms FY26 Revenue View of $367M-$382M

Backs Fy26 revenue view $367M-$382M, consensus $398.63M. The company said, "Certara is reaffirming its revenue growth and updating its adjusted EBITDA margin, adjusted diluted earnings per share, and fully diluted share guidance for the full year 2026, to reflect the divestiture of the Regulatory and Medical Writing business and Continuing Operations reporting."

7/7 08:30

Certara Partners with Nvidia to Advance AI Platform

Certara (CERT) is partnering with Nvidia (NVDA) to advance Certara's open integrated AI platform. The Nvidia BioNeMo provides access to Nvidia's full life science stack. Within Certara's platform, BioNeMo Agent Toolkit serves as one of several agentic frameworks available to clients, working alongside Certara's biosimulation models, regulatory expertise, and scientific teams to accelerate insight generation.

本页仅供研究参考,不构成投资建议。模型可能出错。过往表现不代表未来结果。

免费开始